First patient dosed in phase 1b/2a study of procizumab

Irish biotech’s germ-free egg platform could help close global shortfall

GlueSEEKER enables rational design of targeted protein degraders

Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients

EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics

First patient dosed in BUOY-1 study targeting MDD with or without anxious distress

Funding to accelerate development of AI-driven tumour profiling tool OneMap

Digital operating rooms and histotripsy therapy combine to improve outcomes

Vertex’s once-daily triple therapy approved for eligible patients aged six and over